An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Retigabine (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors GSK
- 25 Jun 2013 Results presented at the 30th International Epilepsy Congress.
- 01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned End Date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.